Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess clinical trial evidence for antibody-drug conjugates in the management of HR+/HER2–, HER2+, and triple-negative breast cancer (TNBC)
- Develop patient-centered treatment plans for advanced/metastatic breast cancer
- Evaluate strategies for sequencing of antibody-drug conjugates in the management of HR+/HER2–, HER2+, and TNBC
- Implement effective toxicity management approaches to optimize outcomes and minimize adverse events for patients receiving ADCs and targeted therapies for HR+/HER2–, HER2+, and TNBC
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine, Geffen School of Medicine
University of California, Los Angeles
Program Director, Breast Medical Oncology
Assistant Chief of Translational Research, Division of Hematology-Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures: Consultant: Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer; Research (paid to institution): Alyssum, Daiichi Sankyo /AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer.
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, GSK, Genentech, Genzyme, Gilead Sciences, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily.
Hope S. Rugo, MD
Professor, Department of Medical Oncology & Therapeutics Research
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Advisor: Bristol Myers Squibb, Chugai, Mylan, Napo, Sanofi; Grant/Research Support: Ambrx, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Novartis Pharmaceuticals Corporation, OBI Pharma, Pfizer, Stemline Therapeutics.
Paolo Tarantino, MD
Clinical Fellow
Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Advisory Role: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead, Menarini/Stemline, Novartis; Speaker: AstraZeneca, Daiichi Sankyo.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here